Literature DB >> 1825614

Severe hypocalcaemia [corrected] after treatment with diphosphonate and aminoglycoside.

U Pedersen-Bjergaard, J Myhre.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825614      PMCID: PMC1668973          DOI: 10.1136/bmj.302.6771.295

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate.

Authors:  D I Jodrell; T J Iveson; I E Smith
Journal:  Lancet       Date:  1987-03-14       Impact factor: 79.321

Review 2.  Bisphosphonates--history and experimental basis.

Authors:  H Fleisch
Journal:  Bone       Date:  1987       Impact factor: 4.398

3.  Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.

Authors:  S E Papapoulos; H I Harinck; O L Bijvoet; J H Gleed; L J Fraher; J L O'Riordan
Journal:  Bone Miner       Date:  1986-02

4.  Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency.

Authors:  R K Rude; S B Oldham; F R Singer
Journal:  Clin Endocrinol (Oxf)       Date:  1976-05       Impact factor: 3.478

5.  Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapy.

Authors:  M J Keating; M R Sethi; G P Bodey; N A Samaan
Journal:  Cancer       Date:  1977-04       Impact factor: 6.860

  5 in total
  8 in total

Review 1.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

2.  Electrocardiographic Q-Tc prolongation associated with infusion of intravenous pamidronate disodium.

Authors:  N Varma; G N Kerrigan
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

3.  Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.

Authors:  A Mishra; L Wong; J Jonklaas
Journal:  Endocrine       Date:  2001-03       Impact factor: 3.633

Review 4.  Comparative tolerability of drug therapies for hypercalcaemia of malignancy.

Authors:  N Zojer; A V Keck; M Pecherstorfer
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 5.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 6.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

7.  Safety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.

Authors:  Luca Dalle Carbonare; Mirko Zanatta; Adriano Gasparetto; Maria Teresa Valenti
Journal:  Drug Healthc Patient Saf       Date:  2010-08-19

Review 8.  Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice.

Authors:  Oliver Bock; Dieter Felsenberg
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.